Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 7 (2010), Issue 2 (February)

1. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
   Int J Radiat Oncol Biol Phys, 76(2): 342-8. [Abstract] [Full-text]
2. Results of a multi-institution deformable registration accuracy study (MIDRAS).
   Int J Radiat Oncol Biol Phys, 76(2): 583-96. [Abstract] [Full-text]
3. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials.
   Exp Mol Pathol, 88(1): 45-51. [Abstract] [Full-text]
4. Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
   Jpn J Clin Oncol, 40(2): 177-80. [Abstract] [Full-text]
5. Prostate carcinogenesis induced by N-methyl-N-nitrosourea (mnu) in gerbils: histopathological diagnosis and potential invasiveness mediated by extracellular matrix components.
   Exp Mol Pathol, 88(1): 96-106. [Abstract] [Full-text]
6. RhoB enhances migration and MMP1 expression of prostate cancer DU145.
   Exp Mol Pathol, 88(1): 90-5. [Abstract] [Full-text]
7. Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer.
   Exp Mol Pathol, 88(1): 77-81. [Abstract] [Full-text]
8. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
   Int J Radiat Oncol Biol Phys, 76(2): 355-60. [Abstract] [Full-text]
9. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy.
   Int J Radiat Oncol Biol Phys, 76(2): 369-78. [Abstract] [Full-text]
10. Effectiveness of educational intervention on the congruence of prostate and rectal contouring as compared with a gold standard in three-dimensional radiotherapy for prostate.
    Int J Radiat Oncol Biol Phys, 76(2): 379-85. [Abstract] [Full-text]
11. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
    Int J Radiat Oncol Biol Phys, 76(2): 349-54. [Abstract] [Full-text]
12. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Int J Radiat Oncol Biol Phys, 76(2): 386-92. [Abstract] [Full-text]
13. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
    Int J Radiat Oncol Biol Phys, 76(2): 337-41. [Abstract] [Full-text]
14. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 76(2): 361-8. [Abstract] [Full-text]
15. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
    Exp Cell Res, 316(4): 554-67. [Abstract] [Full-text]
16. Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy.
    Eur Urol, 57(3): 371-86. [Abstract] [Full-text]
17. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
    Eur Urol, 57(3): 453-8. [Abstract] [Full-text]
18. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden.
    Eur Urol, 57(3): 390-5. [Abstract] [Full-text]
19. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans.
    Prostate, 70(3): 270-5. [Abstract] [Full-text]
20. Association of CD14 variant with prostate cancer in African American men.
    Prostate, 70(3): 262-9. [Abstract] [Full-text]
21. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.
    Prostate, 70(3): 305-16. [Abstract] [Full-text]
22. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
    Prostate, 70(3): 276-87. [Abstract] [Full-text]
23. Ras responsive element binding protein-1 (RREB-1) down-regulates hZIP1 expression in prostate cancer cells.
    Prostate, 70(3): 288-96. [Abstract] [Full-text]
24. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro.
    Prostate, 70(3): 229-38. [Abstract] [Full-text]
25. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Prostate, 70(3): 252-61. [Abstract] [Full-text]
26. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Prostate, 70(3): 239-51. [Abstract] [Full-text]
27. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
    Prostate, 70(3): 333-40. [Abstract] [Full-text]
28. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
    Eur Urol, 57(3): 446-52. [Abstract] [Full-text]
29. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy.
    Eur Urol, 57(3): 437-43. [Abstract] [Full-text]
30. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
    J Pharm Biomed Anal, 51(4): 907-14. [Abstract] [Full-text]
31. Radiation protection of persons living close to patients with radioactive implants.
    Strahlenther Onkol, 186(2): 107-12. [Abstract] [Full-text]
32. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
    Br J Cancer, 102(3): 570-6. [Abstract] [Full-text]
33. False-positive screening results in the Finnish prostate cancer screening trial.
    Br J Cancer, 102(3): 469-74. [Abstract] [Full-text]
34. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.
    Prostate, 70(4): 341-52. [Abstract] [Full-text]
35. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Prostate, 70(4): 401-11. [Abstract] [Full-text]
36. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
    Prostate, 70(4): 443-55. [Abstract] [Full-text]
37. Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.
    Prostate, 70(4): 362-76. [Abstract] [Full-text]
38. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
    Prostate, 70(4): 433-42. [Abstract] [Full-text]
39. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men.
    Prostate, 70(4): 425-32. [Abstract] [Full-text]
40. Overexpression of hepatocyte nuclear factor-3alpha induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells.
    Prostate, 70(4): 353-61. [Abstract] [Full-text]
41. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Prostate, 70(4): 412-24. [Abstract] [Full-text]
42. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Prostate, 70(4): 390-400. [Abstract] [Full-text]
43. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex.
    Int J Cancer, 126(7): 1538-48. [Abstract] [Full-text]
44. Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3.
    Int J Cancer, 126(7): 1562-9. [Abstract] [Full-text]
45. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
    Proc Natl Acad Sci U S A, 107(5): 2136-40. [Abstract] [Full-text]
46. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells.
    J Virol, 84(5): 2556-62. [Abstract] [Full-text]
47. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Cancer, 116(4): 837-42. [Abstract] [Full-text]
48. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Oncogene, 29(6): 898-908. [Abstract] [Full-text]
49. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
    Oncogene, 29(6): 811-21. [Abstract] [Full-text]
50. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype.
    J Pathol, 220(4): 452-60. [Abstract] [Full-text]
51. Emerging cardiometabolic complications of androgen deprivation therapy.
    Aging Male, 13(1): 1-9. [Abstract] [Full-text]
52. Living with a prostate cancer diagnosis: a qualitative 2-year follow-up.
    Aging Male, 13(1): 25-31. [Abstract] [Full-text]
53. Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups.
    Aging Male, 13(1): 10-7. [Abstract] [Full-text]
54. The presence of prostate cancer on saturation biopsy can be accurately predicted.
    BJU Int, 105(5): 636-41. [Abstract] [Full-text]
55. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
    Mol Cell Biol, 30(5): 1243-53. [Abstract] [Full-text]
56. beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.
    BJU Int, 105(5): 716-22. [Abstract] [Full-text]
57. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram.
    BJU Int, 105(5): 642-7. [Abstract] [Full-text]
58. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    BJU Int, 105(5): 648-51. [Abstract] [Full-text]
59. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden.
    BJU Int, 105(5): 652-8. [Abstract] [Full-text]
60. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
    BJU Int, 105(5): 631-5. [Abstract] [Full-text]
61. Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells.
    Int J Radiat Oncol Biol Phys, 76(3): 896-904. [Abstract] [Full-text]
62. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium.
    Cancer Invest, 28(3): 275-9. [Abstract] [Full-text]
63. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
    Int J Radiat Oncol Biol Phys, 76(3): 935-42. [Abstract] [Full-text]
64. Reduction of dose delivered to organs at risk in prostate cancer patients via image-guided radiation therapy.
    Int J Radiat Oncol Biol Phys, 76(3): 924-34. [Abstract] [Full-text]
65. Management of anaemia in prostate cancer.
    Cancer Invest, 28(3): 280-8. [Abstract] [Full-text]
66. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences.
    Int J Radiat Oncol Biol Phys, 76(3): 741-6. [Abstract] [Full-text]
67. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.
    Int J Radiat Oncol Biol Phys, 76(3): 747-54. [Abstract] [Full-text]
68. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
    Int J Radiat Oncol Biol Phys, 76(3): 735-40. [Abstract] [Full-text]
69. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
    Int J Radiat Oncol Biol Phys, 76(3): 755-60. [Abstract] [Full-text]
70. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
    J Urol, 183(3): 1003-9. [Abstract] [Full-text]
71. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
    J Urol, 183(3): 997-1001. [Abstract] [Full-text]
72. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
    J Urol, 183(3): 940-4. [Abstract] [Full-text]
73. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.
    J Urol, 183(3): 984-9. [Abstract] [Full-text]
74. Variations among experienced surgeons in cancer control after open radical prostatectomy.
    J Urol, 183(3): 977-82. [Abstract] [Full-text]
75. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
    J Urol, 183(3): 946-50. [Abstract] [Full-text]
76. Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.
    J Urol, 183(3): 958-62. [Abstract] [Full-text]
77. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival.
    J Urol, 183(3): 990-6. [Abstract] [Full-text]
78. Discrepancy between local and central pathological review of radical prostatectomy specimens.
    J Urol, 183(3): 952-7. [Abstract] [Full-text]
79. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection.
    J Urol, 183(3): 970-5. [Abstract] [Full-text]
80. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
    J Clin Oncol, 28(6): 1069-74. [Abstract] [Full-text]
81. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.
    Mol Pharmacol, 77(3): 378-87. [Abstract] [Full-text]
82. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.
    Blood, 115(7): 1374-84. [Abstract] [Full-text]
83. Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation.
    Biochem Biophys Res Commun, 392(4): 538-42. [Abstract] [Full-text]
84. Differentiation of prostate cancer from normal prostate tissue: role of hotspots in pharmacokinetic MRI and histologic evaluation.
    AJR Am J Roentgenol, 194(3): 675-81. [Abstract] [Full-text]
85. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
    Endocrinology, 151(3): 896-908. [Abstract] [Full-text]
86. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5.
    Life Sci, 86(9): 351-7. [Abstract] [Full-text]
87. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.
    Am J Clin Nutr, 91(3): 712-21. [Abstract] [Full-text]
88. Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer.
    Eur J Surg Oncol, 36(3): 281-6. [Abstract] [Full-text]
89. Aromatase and regulating the estrogen:androgen ratio in the prostate gland.
    J Steroid Biochem Mol Biol, 118(4): 246-51. [Abstract] [Full-text]
90. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
    Eur J Pharmacol, 631(1): 1-9. [Abstract] [Full-text]
91. Breast and prostate cancer: more similar than different.
    Nat Rev Cancer, 10(3): 205-12. [Abstract] [Full-text]
92. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    J Clin Oncol, 28(7): 1112-6. [Abstract] [Full-text]
93. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
    J Clin Oncol, 28(7): 1106-11. [Abstract] [Full-text]
94. Time trends and local variation in primary treatment of localized prostate cancer.
    J Clin Oncol, 28(7): 1117-23. [Abstract] [Full-text]
95. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(7): 1099-105. [Abstract] [Full-text]
96. Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers.
    Cancer, 116(5): 1378-84. [Abstract] [Full-text]
97. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    Cancer, 116(5): 1281-90. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.